Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

ProMIS Neurosciences Inc PMN

Healthcare Biotechnology
ProMIS Neurosciences Inc. is a development stage biotechnology company. The Company is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), an alpha-synucleinopathy. Its proprietary target discovery engine applies a thermodynamic, computational discovery platform - ProMIS and Collective Coordinates - to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product portfolio includes PMN310 / Amyloid-beta, PMN267 / TDP-43, and PMN442 / Alpha-synuclein. The Company plans to investigate additional synucleinopathies, including Parkinson's disease (PD) and dementia with Lewy bodies (DLB). Its wholly owned subsidiary is ProMIS Neurosciences (US) Inc.


NDAQ:PMN - Post by User

ProMIS Neurosciences Inc > PMN Announces Strategic Priorities for 2021
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(84)
•••
Comment by M101on Jan 13, 2021 7:25pm
119 Views
Post# 32290975

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:PMN Announces Strategic Priorities for 2021

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:PMN Announces Strategic Priorities for 2021FJ is right about the field being packed and getting more so, and the 2021 outlook says nothing that differentiates Promis' potential covid test entry within that field. Shareholders who want to try to figure it out can always listen to Elliot on Saving Minds, but he's not close to making the case that there will be a niche or segment remaining for Promis/BCNI to fill.  Elliot seems to be satisfied with not attracting new shareholders, as long as he gets overpaid. 
 
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities